HNSPF
Hansoh Pharmaceutical Group Company Limited
Price Chart
Latest Quote
$3.83
+0.00 (+0.00%)
Current Price
| Previous Close | $3.83 |
| Open | $5.16 |
| Day High | $5.16 |
| Day Low | $5.16 |
| Volume | 109 |
Stock Information
Note: Financial values converted from CNY to USD
| Quarterly Dividend / Yield | $0.06 / 1.45% |
| Shares Outstanding | 6.06B |
| Quarterly Dividend Yield | 1.45% |
| Quarterly Dividend | $0.06 |
| Total Debt | $15.43M |
| Cash Equivalents | $4.64B |
| Revenue | $2.21B |
| Net Income | $815.77M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $23.19B |
| P/E Ratio | 27.32 |
| EPS (TTM) | $0.14 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-8.31B |
| Sales | $2.21B |
| Income | $815.77M |
| Book/sh | $0.86 |
| Cash/sh | $5.21 |
| Employees | 9K |
Financial Ratios
| Quick Ratio | 7.92 |
| Current Ratio | 8.09 |
| Debt/Eq | 0.30 |
| EPS Growth TTM | 47.00% |
Returns & Margins
| ROA | 9.44% |
| ROE | 17.35% |
| Gross Margin | 89.89% |
| Operating Margin | 29.60% |
| Profit Margin | 36.97% |
Ownership
| Insider Ownership | 79.55% |
| Institutional Ownership | 16.06% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 1.54 |
| P/B | 4.44 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $4.16 |
| SMA50 | $4.50 |
| SMA200 | $4.75 |
| ATR | 0.0474 |
| Shares Float | 1.24B |
| Volatility | 0.52 |
Performance History
| Week | +0.00% |
| Month | -14.79% |
| Quarter | -25.87% |
| 6 Months | -23.12% |
| YTD | -23.12% |
| Year | +17.74% |
| 3 Years | +187.29% |
| 10 Years | +195.36% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $3.83 | 0 |
| 2026-06-22 | $3.83 | 0 |
| 2026-06-18 | $3.83 | 0 |
| 2026-06-17 | $3.83 | 0 |
| 2026-06-16 | $3.83 | 0 |
| 2026-06-15 | $3.83 | 0 |
| 2026-06-12 | $3.83 | 0 |
| 2026-06-11 | $3.83 | 0 |
| 2026-06-10 | $3.83 | 0 |
| 2026-06-09 | $3.83 | 110 |
| 2026-06-08 | $4.49 | 0 |
| 2026-06-05 | $4.49 | 0 |
| 2026-06-04 | $4.49 | 0 |
| 2026-06-03 | $4.49 | 0 |
| 2026-06-02 | $4.49 | 0 |
| 2026-06-01 | $4.49 | 0 |
| 2026-05-29 | $4.49 | 0 |
| 2026-05-28 | $4.49 | 0 |
| 2026-05-27 | $4.49 | 0 |
| 2026-05-26 | $4.49 | 0 |
About Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.
đ° Latest News
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
Zacks âĸ 2026-03-23T14:51:00Z
Terns Pharmaceuticals (TERN) Valuation Check After Expanded Global Rights To TERN-701
Simply Wall St. âĸ 2026-02-03T13:23:21Z
Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment
Insider Monkey âĸ 2026-02-02T09:16:54Z
Hansoh Pharmaceutical Group (SEHK:3692) Valuation: Is Recent Momentum Supported by the Fundamentals?
Simply Wall St. âĸ 2025-09-10T11:05:09Z
China's healthcare sector sees record US$10.6 billion fundraising as biotech booms
South China Morning Post âĸ 2025-09-10T09:30:00Z
BofAâs momentum indicator lists top-ranked stocks globally
Investing.com âĸ 2025-07-03T10:53:49Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $159,319,714 | $148,575,728 | $124,960,001 | $125,396,996 |
| Cost Of Revenue | $159,319,714 | $148,575,728 | $124,960,001 | $125,396,996 |
| Total Revenue | $1,767,120,715 | $1,456,236,501 | $1,352,263,485 | $1,431,927,233 |
| Operating Revenue | $1,767,120,715 | $1,456,236,501 | $1,352,263,485 | $1,431,927,233 |
| Expenses | ||||
| Interest Expense | $964,069 | $9,610,279 | $8,379,862 | $7,612,527 |
| Total Expenses | $1,186,125,963 | $1,047,012,207 | $949,933,963 | $994,514,767 |
| Rent Expense Supplemental | $649,583 | $786,504 | $1,246,847 | - |
| Other Non Operating Income Expenses | $-6,998,400 | $-23,839,412 | $-31,076,920 | $14,304,080 |
| Net Non Operating Interest Income Expense | $142,480,142 | $120,825,847 | $36,167,792 | $16,037,790 |
| Interest Expense Non Operating | $964,069 | $9,610,279 | $8,379,862 | $7,612,527 |
| Operating Expense | $1,026,806,249 | $898,436,479 | $824,973,962 | $869,117,771 |
| Selling And Marketing Expense | $547,086,159 | $508,937,766 | $511,685,845 | $494,042,907 |
| General And Administrative Expense | $102,697,488 | $102,308,055 | $86,110,428 | $135,973,217 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $630,100,295 | $472,378,379 | $372,389,047 | $391,003,837 |
| Net Interest Income | $142,480,142 | $120,825,847 | $36,167,792 | $16,037,790 |
| Interest Income | $143,444,211 | $130,436,126 | $44,547,655 | $23,650,317 |
| Normalized Income | $624,908,256 | $455,282,774 | $363,738,195 | $394,059,397 |
| Net Income From Continuing And Discontinued Operation | $630,100,295 | $472,378,379 | $372,389,047 | $391,003,837 |
| Average Dilution Earnings | $77,108 | $-18,990,098 | $0 | $-8,532,349 |
| Net Income Common Stockholders | $630,100,295 | $472,378,379 | $372,389,047 | $391,003,837 |
| Net Income | $630,100,295 | $472,378,379 | $372,389,047 | $391,003,837 |
| Net Income Including Noncontrolling Interests | $630,100,295 | $472,378,379 | $372,389,047 | $391,003,837 |
| Net Income Continuous Operations | $630,100,295 | $472,378,379 | $372,389,047 | $391,003,837 |
| Pretax Income | $732,914,670 | $542,806,580 | $424,949,616 | $475,632,634 |
| Special Income Charges | $-2,791,029 | $-1,606,878 | $131,300 | $-8,867,878 |
| Interest Income Non Operating | $143,444,211 | $130,436,126 | $44,547,655 | $23,650,317 |
| Operating Income | $580,994,752 | $409,224,294 | $402,329,522 | $437,412,466 |
| Gross Profit | $1,607,801,001 | $1,307,660,774 | $1,227,303,484 | $1,306,530,237 |
| Per Share | ||||
| Diluted EPS | $0.11 | $0.07 | $0.06 | $0.06 |
| Basic EPS | $0.11 | $0.08 | $0.06 | $0.07 |
| Other | ||||
| Tax Effect Of Unusual Items | $847,192 | $2,548,831 | $1,221,018 | $-661,345 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $785,684,944 | $585,578,007 | $473,124,239 | $527,096,825 |
| Total Unusual Items | $6,039,231 | $19,644,437 | $9,871,870 | $-3,716,905 |
| Total Unusual Items Excluding Goodwill | $6,039,231 | $19,644,437 | $9,871,870 | $-3,716,905 |
| Reconciled Depreciation | $57,845,436 | $52,805,585 | $49,666,632 | $40,134,758 |
| EBITDA (Bullshit earnings) | $791,724,175 | $605,222,444 | $482,996,109 | $523,379,920 |
| EBIT | $733,878,739 | $552,416,859 | $433,329,478 | $483,245,162 |
| Diluted Average Shares | $857,557,125 | $867,597,246 | $854,601,724 | $864,456,359 |
| Basic Average Shares | $854,689,983 | $853,941,006 | $852,632,782 | $853,384,834 |
| Diluted NI Availto Com Stockholders | $630,177,403 | $453,388,281 | $372,389,047 | $382,471,488 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Tax Provision | $102,814,375 | $70,428,201 | $52,560,568 | $84,628,797 |
| Other Special Charges | $-824,554 | $-1,856,218 | $-1,620,426 | $8,700,114 |
| Write Off | $-993,039 | $3,463,096 | $1,489,126 | $167,764 |
| Impairment Of Capital Assets | $4,608,622 | $0 | - | - |
| Research And Development | $389,382,114 | $302,242,039 | $244,053,147 | $258,998,883 |
| Selling General And Administration | $649,783,646 | $611,245,821 | $597,796,273 | $630,016,125 |
Fetched: 2026-02-06
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,098,212,416 | $3,692,166,133 | $3,259,230,844 | $2,884,252,258 |
| Total Assets | $4,562,767,265 | $4,761,840,519 | $4,324,096,416 | $3,914,528,089 |
| Total Non Current Assets | $607,649,407 | $598,961,112 | $601,049,087 | $573,743,264 |
| Investmentin Financial Assets | $101,218,307 | $98,684,978 | $59,463,988 | $56,925,614 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $101,218,307 | $98,684,978 | $59,463,988 | $56,925,614 |
| Goodwill And Other Intangible Assets | $35,352,463 | $25,570,528 | $4,817,030 | $2,455,501 |
| Other Intangible Assets | $35,352,463 | $25,570,528 | $4,817,030 | $2,455,501 |
| Current Assets | $3,955,117,858 | $4,162,879,407 | $3,723,047,328 | $3,340,784,825 |
| Prepaid Assets | $20,215,902 | $22,385,886 | $19,380,107 | $15,489,529 |
| Inventory | $93,859,300 | $82,986,032 | $64,553,275 | $59,110,587 |
| Other Receivables | $9,398,267 | $2,630,904 | $11,366,617 | $61,786,459 |
| Taxes Receivable | $10,283,354 | $9,692,864 | $1,870,631 | $7,600,709 |
| Accounts Receivable | $450,755,792 | $462,596,444 | $509,342,188 | $468,024,863 |
| Allowance For Doubtful Accounts Receivable | $-1,790,784 | $-4,410,879 | $-1,184,872 | $-154,072 |
| Gross Accounts Receivable | $452,546,577 | $467,007,323 | $510,527,060 | $468,178,936 |
| Cash Cash Equivalents And Short Term Investments | $3,370,605,241 | $3,582,587,277 | $3,116,534,511 | $2,728,772,678 |
| Cash And Cash Equivalents | $3,260,390,206 | $3,233,456,376 | $2,538,845,756 | $2,118,970,870 |
| Cash Equivalents | $2,957,484,460 | $2,909,643,059 | $2,183,669,714 | $1,758,181,782 |
| Cash Financial | $302,905,747 | $323,813,317 | $355,176,042 | $360,789,088 |
| Debt | ||||
| Total Debt | $16,991,626 | $620,286,652 | $630,969,528 | $551,702,995 |
| Long Term Debt And Capital Lease Obligation | $8,793,652 | $15,054,119 | $628,729,354 | $550,266,332 |
| Long Term Debt | $0 | $5,727,916 | $617,260,983 | $539,468,731 |
| Current Debt And Capital Lease Obligation | $8,197,973 | $605,232,533 | $2,240,174 | $1,436,663 |
| Current Debt | $5,891,068 | $602,913,953 | $0 | - |
| Net Debt | - | - | $232,997,990 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $429,202,386 | $1,044,103,858 | $1,060,048,541 | $1,027,820,331 |
| Total Non Current Liabilities Net Minority Interest | $40,747,300 | $54,978,451 | $682,506,214 | $592,017,625 |
| Other Non Current Liabilities | $3,100,904 | $3,168,932 | $3,236,960 | $3,304,988 |
| Non Current Deferred Taxes Liabilities | $28,852,744 | $36,755,400 | $50,539,900 | $38,446,304 |
| Current Liabilities | $388,455,086 | $989,125,407 | $377,542,327 | $435,802,706 |
| Payables | $162,624,414 | $155,451,187 | $141,493,445 | $182,544,566 |
| Other Payable | $101,360,705 | $99,102,515 | $87,681,706 | $111,145,667 |
| Total Tax Payable | $29,865,384 | $32,745,917 | $21,772,768 | $35,607,713 |
| Accounts Payable | $31,398,324 | $23,602,755 | $32,038,971 | $35,791,187 |
| Dividends Payable | - | - | $0 | - |
| Equity | ||||
| Common Stock Equity | $4,133,564,879 | $3,717,736,661 | $3,264,047,874 | $2,886,707,758 |
| Total Equity Gross Minority Interest | $4,133,564,879 | $3,717,736,661 | $3,264,047,874 | $2,886,707,758 |
| Stockholders Equity | $4,133,564,879 | $3,717,736,661 | $3,264,047,874 | $2,886,707,758 |
| Other Equity Interest | $66,741,419 | $46,891,456 | $45,180,807 | - |
| Retained Earnings | $1,875,280,780 | $1,514,256,188 | $1,137,182,131 | - |
| Long Term Equity Investment | - | $0 | $34,744,965 | $0 |
| Other | ||||
| Treasury Shares Number | $189,537 | $1,385,743 | $345,569 | - |
| Ordinary Shares Number | $855,300,987 | $853,773,288 | $853,228,059 | $853,573,628 |
| Share Issued | $855,490,524 | $855,159,031 | $853,573,628 | $853,573,628 |
| Tangible Book Value | $4,098,212,416 | $3,692,166,133 | $3,259,230,844 | $2,884,252,258 |
| Invested Capital | $4,139,455,947 | $4,326,378,531 | $3,881,308,858 | $3,426,176,489 |
| Working Capital | $3,566,662,771 | $3,173,754,001 | $3,345,505,001 | $2,904,982,119 |
| Capital Lease Obligations | $11,100,557 | $11,644,783 | $13,708,545 | $12,234,265 |
| Total Capitalization | $4,133,564,879 | $3,723,464,577 | $3,881,308,858 | $3,426,176,489 |
| Treasury Stock | $1,904,645 | $15,656,428 | $4,039,462 | $8,354,928 |
| Additional Paid In Capital | $2,017,783,118 | $2,031,552,629 | $2,007,918,454 | - |
| Capital Stock | $7,495 | $7,495 | $7,495 | $7,495 |
| Common Stock | $7,495 | $7,495 | $7,495 | $7,495 |
| Long Term Capital Lease Obligation | $8,793,652 | $9,326,204 | $11,468,371 | $10,797,601 |
| Current Capital Lease Obligation | $2,306,905 | $2,318,579 | $2,240,174 | $1,436,663 |
| Net PPE | $471,078,637 | $474,705,606 | $502,023,104 | $514,362,149 |
| Accumulated Depreciation | $-324,366,334 | $-282,864,815 | $-237,031,399 | $-195,979,125 |
| Gross PPE | $795,444,971 | $757,570,421 | $739,054,503 | $710,341,274 |
| Construction In Progress | $26,563,999 | $54,919,359 | $56,471,180 | $85,768,990 |
| Machinery Furniture Equipment | $340,554,017 | $326,906,582 | $306,987,870 | $258,421,941 |
| Buildings And Improvements | $374,317,906 | $352,351,431 | $351,633,099 | $341,618,687 |
| Land And Improvements | $54,009,050 | $23,393,050 | $23,962,353 | $24,531,657 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $30,589,048 | $21,629,505 | $16,331,233 | $14,804,346 |
| Work In Process | $40,712,998 | $41,454,966 | $33,111,424 | $30,587,175 |
| Raw Materials | $22,557,254 | $19,901,560 | $15,110,617 | $13,719,066 |
| Other Short Term Investments | $110,215,035 | $349,130,901 | $577,688,755 | $609,801,808 |
| Minority Interest | - | $0 | $0 | $0 |
| Investmentsin Associatesat Cost | - | $0 | $34,744,965 | $0 |
| Other Properties | - | - | $497,224,522 | $500,900,062 |
Fetched: 2026-02-06
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $481,014,068 | $396,919,119 | $353,023,353 | $302,901,423 |
| Operating Activities | ||||
| Operating Cash Flow | $556,671,648 | $449,168,804 | $395,083,078 | $371,425,555 |
| Investing Activities | ||||
| Capital Expenditure | $-75,657,580 | $-52,249,685 | $-42,059,725 | $-68,524,132 |
| Investing Cash Flow | $-200,595,529 | $154,788,921 | $-855,407,353 | $-325,606,696 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $-73,073 | $-11,080,235 | $-9,148,494 | $-6,177,017 |
| Financing Cash Flow | $-874,269,609 | $-108,628,191 | $-117,917,066 | $492,451,451 |
| Cash Dividends Paid | $-267,839,089 | $-93,982,961 | $-102,645,314 | $-54,893,272 |
| Common Stock Dividend Paid | $-267,839,089 | $-93,982,961 | $-102,645,314 | $-54,893,272 |
| Net Common Stock Issuance | $-73,073 | $-11,080,235 | $-9,148,494 | $-6,177,017 |
| Common Stock Issuance | $-73,073 | $-11,080,235 | $-9,148,494 | $-6,177,017 |
| Other | ||||
| Repayment Of Debt | $-674,977,713 | $-129,714,768 | $-3,576,236 | $0 |
| Issuance Of Debt | $72,063,760 | $129,714,768 | $0 | $555,292,924 |
| End Cash Position | $334,765,135 | $861,956,507 | $384,262,993 | $968,350,866 |
| Beginning Cash Position | $861,956,507 | $384,262,993 | $968,350,866 | $441,508,138 |
| Effect Of Exchange Rate Changes | $-8,997,881 | $-17,636,020 | $-5,846,533 | $-11,427,583 |
| Changes In Cash | $-518,193,491 | $495,329,534 | $-578,241,340 | $538,270,311 |
| Interest Paid Cff | $-462,217 | $-831,904 | $0 | - |
| Net Issuance Payments Of Debt | $-602,913,953 | $0 | $-3,576,236 | $555,292,924 |
| Net Long Term Debt Issuance | $-602,913,953 | $0 | $-3,576,236 | $555,292,924 |
| Long Term Debt Payments | $-674,977,713 | $-129,714,768 | $-3,576,236 | $0 |
| Long Term Debt Issuance | $72,063,760 | $129,714,768 | $0 | $555,292,924 |
| Interest Received Cfi | $126,239,277 | $78,062,492 | $16,022,945 | $21,643,630 |
| Net Investment Purchase And Sale | $-238,981,732 | $125,836,441 | $-795,968,443 | $-286,655,801 |
| Sale Of Investment | $275,983,302 | $326,532,859 | $86,784,945 | $1,066,905,120 |
| Purchase Of Investment | $-514,965,035 | $-200,696,419 | $-882,753,388 | $-1,353,560,921 |
| Net Business Purchase And Sale | $-15,648,069 | $1,559,604 | $-36,442,788 | $0 |
| Sale Of Business | $0 | $35,992,101 | $0 | - |
| Purchase Of Business | $-15,648,069 | $-34,432,497 | $-36,442,788 | $0 |
| Net Intangibles Purchase And Sale | $-43,666,459 | $-20,599,570 | $-2,738,711 | $-2,185,117 |
| Purchase Of Intangibles | $-43,666,459 | $-20,599,570 | $-2,738,711 | $-2,220,717 |
| Net PPE Purchase And Sale | $-28,538,546 | $-30,070,045 | $-36,280,356 | $-58,409,407 |
| Sale Of PPE | $3,452,575 | $1,580,070 | $3,040,658 | $7,894,008 |
| Purchase Of PPE | $-31,991,121 | $-31,650,115 | $-39,321,014 | $-66,303,415 |
| Taxes Refund Paid | $-116,335,266 | $-84,974,415 | $-46,702,073 | $-46,039,951 |
| Change In Working Capital | $5,212,084 | $37,074,210 | $-44,071,601 | $-61,740,915 |
| Change In Other Current Assets | $-2,773,590 | $1,927,561 | $417,393 | $-25,004,251 |
| Change In Payable | $11,213,121 | $12,389,057 | $-48,499,199 | $61,155,180 |
| Change In Prepaid Assets | $240,837 | $-7,829,295 | $-3,124,541 | $-2,610,005 |
| Change In Inventory | $-12,500,324 | $-18,669,847 | $-5,901,013 | $-16,105,818 |
| Change In Receivables | $9,032,039 | $49,256,733 | $13,035,758 | $-79,176,021 |
| Other Non Cash Items | $-129,465,427 | $-106,720,231 | $-26,445,094 | $-13,199,342 |
| Stock Based Compensation | $19,849,963 | $24,698,412 | $25,858,783 | $9,436,317 |
| Depreciation And Amortization | $57,845,436 | $52,805,585 | $49,666,632 | $40,134,758 |
| Amortization Cash Flow | $1,907,816 | $1,551,100 | $1,273,223 | $901,662 |
| Depreciation | $55,937,620 | $51,254,485 | $48,393,409 | $39,233,096 |
| Gain Loss On Investment Securities | $-18,611,619 | $-18,916,449 | $9,960,653 | $-32,398,569 |
| Gain Loss On Sale Of PPE | $1,646,225 | $179,151 | $-1,620,426 | $-567,142 |
| Gain Loss On Sale Of Business | $0 | $-1,553,118 | $0 | - |
| Net Income From Continuing Operations | $732,914,670 | $542,806,580 | $424,949,616 | $475,632,634 |
| Sale Of Intangibles | - | - | $0 | $35,599 |
Fetched: 2026-02-06